Table 2.
Adverse events during neoadjuvant immune checkpoint inhibitors plus chemotherapy and postoperative complications.
| Events (%) | All patients (N=34, %) | Grade | Pembrolizumab (N=20) | Camrelizumab (N=14) |
|---|---|---|---|---|
| All events during neoadjuvant therapy | 20 (58.8%) | / | 6 (30%) | 14 (100%) |
| Nausea/vomiting/diarrhea | 8 | I | 4 | 4 |
| Reactive capillary endothelial proliferation | 7 | I/II | 0 | 7 |
| Fatigue | 3 | I | 1 | 2 |
| Leukopenia | 2 | I | 1 | 1 |
| All postoperative complications | 7 (20.6%) | / | 5 (25%) | 2 (14.3%) |
| Anastomotic leak | 3 | II | 2 | 1 |
| Pneumonia | 2 | II | 2 | 0 |
| hoarseness | 1 | I | 1 | 0 |
| Subcutaneous emphysema | 1 | I | 0 | 1 |
| 90-day Postoperative mortality | 0 | / | 0 | 0 |
Drugs toxicity was assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Postoperative complications were evaluated by the Clavien-Dindo classification.